CYP4F3 Gene Associated with Disease Development (G4051)

Target Name: CYP4F3

NCBI ID: G4051

CYP4F3

CYP4F3 Gene Associated with Disease Development

CYP4F3 (CP4F3_HUMAN), a gene encoding a protein known as CYP4F3, is a potential drug target and biomarker for various diseases. The CYP4F3 gene is located on chromosome 16 and encodes a protein that is a key regulator of the cytochrome P450 (CYP) enzyme family. This enzyme is responsible for metabolizing a wide variety of drugs, including many statins, antidepressants, and benzodiazepines.

The CYP4F3 gene was first identified in 2008 as a potential drug target due to its association with several diseases, including cardiovascular disease, addiction, and neurodegenerative disorders. Studies have shown that individuals with certain genetic variations in the CYP4F3 gene are at increased risk of developing these diseases. For example, individuals with a genetic variation known as the 220-base pair deletion (c.843-854del) in the CYP4F3 gene are at increased risk of developing cardiovascular disease and other disorders.

In addition to its potential as a drug target, CYP4F3 has also been shown to be a potential biomarker for several diseases. For example, individuals with certain genetic variations in the CYP4F3 gene have been shown to have altered levels of the metabolite of the drug simvastatin , which is used to treat hyperlipidemia (elevated cholesterol levels). These individuals have been shown to have reduced levels of simvastatin metabolite in their blood, which may indicate that they are less responsive to the effects of simvastatin.

Another potential application of CYP4F3 as a biomarker is its association with the disease addiction. Studies have shown that individuals with certain genetic variations in the CYP4F3 gene may be at increased risk of developing addiction, as have been seen in individuals with certain genetic variations in the gene. For example, individuals with a genetic variation known as the 55-base pair insertion (c.55-60ins) in the CYP4F3 gene have been shown to have an increased risk of developing addiction compared to individuals without this variation.

In addition to its potential as a drug target and biomarker, CYP4F3 has also been shown to play a role in the regulation of cellular processes. Studies have shown that the CYP4F3 protein functions as a negative regulator of the transcription factor p21, which is involved in the regulation of cell cycle progression and the maintenance of cellular stability.

In conclusion, CYP4F3 is a gene encoding a protein that is involved in the regulation of several cellular processes and has been shown to be associated with the development of several diseases, including cardiovascular disease, addiction, and neurodegenerative disorders. Further research is needed to fully understand the role of CYP4F3 as a drug target and biomarker.

Protein Name: Cytochrome P450 Family 4 Subfamily F Member 3

Functions: A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids and their oxygenated derivatives (oxylipins) (PubMed:8486631, PubMed:9675028, PubMed:11461919, PubMed:15145985, PubMed:16547005, PubMed:16820285, PubMed:18182499, PubMed:18065749, PubMed:18577768). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:9675028). May play a role in inactivation of pro-inflammatory and anti-inflammatory oxylipins during the resolution of inflammation (PubMed:8486631, PubMed:9675028, PubMed:11461919, PubMed:15145985, PubMed:15364545, PubMed:16547005, PubMed:16820285, PubMed:18182499, PubMed:18065749, PubMed:18577768)

The "CYP4F3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP4F3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets